ASCO 2023 – Gregory Lubiniecki

With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.

At ASCO 2023 Keytruda didn’t take centre stage, but Merck had plenty of new studies to show off. So it was that editor-in-chief Jonah Comstock caught up with Gregory Lubiniecki, VP Clinical Oncology at Merck, to discuss some of the company’s highlights this year, including KEYNOTE-671, which looked at neo-adjuvant Keytruda plus chemotherapy in early-stage non-small cell lung cancer, and KEYNOTE-483 which dealt with plural mesothelioma.

They also get into ASCO trends, and talk a little bit about the future of digital health and artificial intelligence in the oncology space.

Check out the video below to learn more.